2023 / 01

Next Paper
DOI: 10.24075/brsmu.2023.004

ORIGINAL RESEARCH

Adipokines and myokines as indicators of obese phenotypes and their association with the gut microbiome diversity indices

Shestopalov AV2,3, Ganenko LA1, Grigoryeva TV4, Laikov AV4, Vasilyev IYu4, Kolesnikova IM3, Naboka YuL4, Volkova NI1, Roumiantsev SA2,3
About authors

1 Rostov State Medical University, Rostov-on-Don, Russia

2 Center for Molecular Health, Institute of Digital and Translational Biomedicine, Moscow, Russia

3 Pirogov Russian National Research Medical University, Moscow, Russia

4 Kazan Federal University, Kazan, Republic of Tatarstan, Russia

Correspondence should be addressed: Lilia A. Ganenko
Nakhichevansky pereulok, 29, Rostov-on-Don, 344022, Russia; ur.xednay@ailil.oknenag

About paper

Funding: the study was conducted as part of the State Assignment № 0373100122119000041, the project “Creation of a bank of blood serum and fecal samples from healthy donors and patients with obesity, metabolic syndrome, type 2 diabetes mellitus, impaired mucosal barrier of the gastrointestinal tract with the aim of identifying candidate species-specific mediators of quorum sensing microbiota systems human modulating endocrine and metabolic function of adipose tissue”.

Author contribution: Ganenko LA — study concept, data acquisition and analysis, manuscript writing; Volkova NI — research planning and management, manuscript editing; Roumiantsev SA — study design, manuscript editing; Grigoryeva TV — working with the database, analysis of the results; Laikov AV — data analysis and interpretation of the results; Vasilyev IYu — study concept, manuscript editing; Gaponov AM — literature review, study design, manuscript editing; Naboka YuL — data analysis and interpretation of the results, manuscript editing; Shestopalov AV — search for sources of funding, working with data sets, statistical data processing, manuscript writing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Rostov State Medical University (protocol № 20/19 of 12 December 2019); the informed consent was submitted by all study participants.

Received: 2022-12-19 Accepted: 2023-01-21 Published online: 2023-02-17
|
  1. Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018; 7 (1): 57–62. DOI: 10.1080/21623945.2017.1402151.
  2. Iacobini C, Pugliese G, Blasetti Fantauzzi C, at al. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019; 92: 51–60. DOI: 10.1016/j.metabol.2018.11.009.
  3. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019; 129 (10): 3978–89. DOI: 10.1172/JCI129186.
  4. Garvey WT, Garber AJ, Mechanick JI, et al. The Aace Obesity Scientific Committee.American association of clinical endocrinologists and Аmerican college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014; 20 (9): 977– 89. DOI: 10.4158/EP14280.PS.
  5. Graf C, Ferrari N. Metabolic Health-The Role of AdipoMyokines. Int J Mol Sci. 2019; 20 (24): 6159. DOI: 10.3390/ijms20246159.
  6. Bakhai A. Adipokines--targeting a root cause of cardiometabolic risk. QJM. 2008; 101 (10): 767–76. DOI: 10.1093/qjmed/hcn066.
  7. Doumatey AP, Bentley AR, Zhou J, Huang H, Adeyemo A, Rotimi CN. Paradoxical Hyperadiponectinemia is Associated With the Metabolically Healthy Obese (MHO) Phenotype in African Americans. J Endocrinol Metab. 2012; 2 (2): 51–65. DOI: 10.4021/jem95W.
  8. Bluher S. Metabolically healthy obesity from childhood to adulthood — does weight status alone matter? Metabolism. 2014; 63: 1084–109.
  9. Wang HY. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of Inflammation. 2018; ID 9471583.
  10. Amor M, Itariu BK, Moreno-Viedma V, Keindl M, Jürets A, Prager G, et al. Serum Myostatin is Upregulated in Obesity and Correlates with Insulin Resistance in Humans. Exp Clin Endocrinol Diabetes. 2019; 127 (8): 550–6.
  11. Staiger H, Keuper M, Berti L, Hrabe de Angelis M, Häring HU. Fibroblast Growth Factor 21-Metabolic Role in Mice and Men. Endocr Rev. 2017; 38 (5): 468–88.
  12. Hu C, Zhang X, Zhang N, Wei WY, Li LL, Ma ZG, et al. Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clin Transl Med. 2020; 10 (3): e124.
  13. Fu J, Li Y, Esangbedo IC, Li G, Feng D, Li L, et al. Circulating Osteonectin and Adipokine Profiles in Relation to Metabolically Healthy Obesity in Chinese Children: Findings From BCAMS. J Am Heart Assoc. 2018; 7 (23): e009169. DOI: 10.1161/ JAHA.118.009169.
  14. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019; 7 (1): 14. DOI: 10.3390/microorganisms7010014.
  15. Stoma IO, Karpov IA. Mikrobiom cheloveka. Minsk: Doktor Dizajn, 2018; 122 s. Russian.
  16. Bombin A, Yan S, Bombin S, Mosley JD, Ferguson JF. Obesity influences composition of salivary and fecal microbiota and impacts the interactions between bacterial taxa. Physiological Reports. 2022; 10: e15254. Available from: https://doi.org/10.14814/phy2.15254.
  17. Aron-Wisnewsky J, Prifti E, Belda E, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. 2019; 68 (1): 70–82. DOI: 10.1136/gutjnl-2018-316103.
  18. Cotillard A, Kennedy SP, Kong LC, Edi Prifti, Nicolas Pons, Emmanuelle Le Chatelier, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013; 500 (7464): 585–8. DOI: 10.1038/nature12480. Erratum in: Nature. 2013; 502 (7472) 580.
  19. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls dietinduced obesity. Proc Natl Acad Sci USA. 2013; 110 (22): 9066– 71. DOI: 10.1073/pnas.1219451110.
  20. Menshikov VV, redaktor. Metodiki klinicheskix laboratornyx issledovanij. Spravochnoe posobie. Tom 3. M.: Labora, 2009; 880 s. Russian.
  21. Gaponov AM, Volkova NI, Ganenko LA, Naboka YuL, Markelova MI, Sinyagina MN, i dr. Osobennosti mikrobioma tolstoj kishki u pacientov s ozhireniem pri ego razlichnyx fenotipax. Zhurnal mikrobiologii, ehpidemiologii i immunobiologii. 2021; 98 (2): 144–155. Dostupno po ssylke: https://doi.org/10.36233/0372-9311-66. Russian.
  22. Kolesnikova IM, Gaponov AM, Ganenko LA, Volkova NI, Grigoreva TV, Lajkov AV, i dr. Vzaimosvyaz' soderzhaniya nejrotrofov kishechnogo mikrobioma pri razlichnyx metabolicheskix tipax ozhireniya. Zhurnal ehvolyucionnoj bioximii i fiziologii. 2022; 58 (54): 298–310. Russian.
  23. Yosaee S, Khodadost M, Esteghamati A, et al. Adiponectin: An Indicator for Metabolic Syndrome. Iran J Public Health. 2019; 48 (6): 1106–15.
  24. Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A, Smith U. Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab. 2015; 26 (4): 193–200. DOI: 10.1016/j.tem.2015.01.006.
  25. Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients. 2019; 11 (11): 2704. DOI: 10.3390/nu11112704.
  26. Yuan M, Li W, Zhu Y, et al. Asprosin: A novel player in metabolic diseases. Front Endocrinol (Lausanne). 2020; 11: 64. DOI: 10.3389/fendo.2020.00064.
  27. Ugur K, Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol. 2019; 2019: 2521096. DOI: 10.1155/2019/2521096.
  28. Elisha B, Karelis AD, Imbeault P, et al. Effects of acute hyperinsulinaemia on total and high-molecular-weight adiponectin concentration in metabolically healthy but obese postmenopausal women: a Montreal-Ottawa New Emerging Team (MONET) study. Diabetes Metab. 2010; 36 (4): 319–21. DOI: 10.1016/j.diabet.2010.03.004.
  29. Ung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International Journal of Molecular Sciences. 2014; 15 (4): 6184–223. Available from: https://doi.org/10.3390/ijms15046184111,112.
  30. Jamar G, Caranti DA, de Cassia Cesar H, et al. Leptin as a cardiovascular risk marker in metabolically healthy obese: Hyperleptinemia in metabolically healthy obese. Appetite. 2017; 108: 477–82. DOI: 10.1016/j.appet.2016.11.013.
  31. Fu J, Li Y, Esangbedo IC. et al. Circulating osteonectin and adipokine profiles in relation to metabolically healthy obesity in chinese children: findings from BCAMS. J Am Heart Assoc. 2018; 7 (23): e009169. DOI: 10.1161/JAHA.118.009169.